A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Nature Communications"
DOI: 10.1038/s41467-020-15318-5
Abstract: c-MET receptors are activated in cancers through genomic events like tyrosine kinase domain mutations, juxtamembrane splicing mutation and amplified copy numbers, which can be inhibited by c-MET small molecule inhibitors. Here, we discover that the… read more here.
Keywords: polymorphism; squamous cell; her2 signaling; her2 ... See more keywords